Related Experiment Video
Updated: Nov 12, 2025
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Avidity-Based Selection of Tissue-Specific CAR-T Cells from a Combinatorial Cellular Library of CARs
Peixiang Ma1, Ping Ren1, Chuyue Zhang1,2,3,4
1Shanghai Institute for Advanced Immunochemical Studies ShanghaiTech University Shanghai 201210 China.
Abstract:
Using T-cell chimeric antigen receptors (CAR-T) to activate and redirect T cells to tumors expressing the cognate antigen represents a powerful approach in cancer therapy. However, normal tissues with low expression of tumor-associated antigens (TAAs) can be mistargeted, resulting in severe side effects. An approach using a collection of T cells expressing a diverse, 106-member combinatorial cellular library of CARs, in which members can be specifically enriched based on avidity for cell membrane antigens, is reported. Using CD38 as the target antigen, an efficient and effective selection of CARs specifically recognizing CD38+ tumor cells is demonstrated. These selected CAR-T's produce cytokines known to be associated with T cell activation in a CD38 expression-dependent manner. This avidity-based selection endows the engineered T cells with minimal off-tumor effects, while retaining robust antitumor efficacy both in vitro and in vivo. The described method may facilitate the application of CAR-T therapy to TAAs previously considered undruggable.
Insights
This study introduces a new method for engineering T-cell chimeric antigen receptors (CAR-T) to target cancer cells more precisely. The avidity-based selection process minimizes side effects by reducing off-tumor targeting, enhancing CAR-T therapy safety and efficacy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR-T) therapy is a promising cancer treatment that redirects T cells to target tumor cells.
- A significant challenge is the potential for CAR-T cells to target normal tissues expressing low levels of tumor-associated antigens (TAAs), leading to severe side effects.
- Developing CAR-T therapies for TAAs with low tumor specificity remains difficult.
Purpose of the Study:
- To develop a novel CAR-T selection strategy to improve targeting specificity and reduce off-tumor effects.
- To create a large combinatorial library of CARs for efficient screening and selection based on antigen avidity.
- To demonstrate the efficacy and safety of avidity-selected CAR-T cells against CD38-expressing tumors.
Main Methods:
- Construction of a 10^6-member combinatorial cellular library of CARs.
- Avidity-based enrichment of CARs that specifically bind to cell membrane antigens.
- Selection of CD38-specific CARs using CD38 as the target antigen.
- In vitro and in vivo testing of selected CAR-T cells for antitumor efficacy and off-tumor effects.
Main Results:
- Successful selection of CARs with high specificity for CD38-expressing tumor cells.
- Selected CAR-T cells demonstrated CD38-dependent cytokine production, indicating specific T-cell activation.
- Avidity-based selection resulted in minimal off-tumor effects while maintaining robust in vitro and in vivo antitumor efficacy.
Conclusions:
- Avidity-based selection is an effective method for engineering CAR-T cells with improved tumor specificity and reduced toxicity.
- This approach enhances the safety profile of CAR-T therapy by minimizing mistargeting of normal tissues.
- The described method holds potential for expanding CAR-T therapy applications to previously undruggable TAAs.
More Related Videos
Related Concept Videos
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Tumor Immunotherapy